Dr. Soren Thestrup-Nielsen M.D Joins Mainz Biomed's Strategic Advisory Board

As a member of the Strategic Advisory Board, Dr. Soren Thestrup-Nielsen will participate actively in the company’s product development and commercial strategies.

Fremont, CA: "It's a pleasure to welcome Soren to our newly formed Strategic Advisory Board as he brings us tremendous leadership in all aspects of a product's life cycle, commented Guido Baechler, Chief Executive Officer of Mainz Biomed. Dr. Soren Thestrup-Nielsen M.D. has joined the Strategic Advisory Board of Mainz Biomed N.V., a molecular genetics diagnostic company focusing on early cancer detection.  "All of us at the company are excited to work with Soren as we embark on ColoAlerts commercial roll-out across Europe and develop the regulatory and clinical strategy for the U.S. market." added, Baechler.

Dr. Thestrup-Nielsen has worked in the medical device sector for over 25 years, first at Boston Scientific and then at Danaher Corporation, where he supervised Danaher's acute care and laboratory diagnostics portfolio's inorganic growth.

He has held a number of notable executive positions in the past, including Chairman of Althea Group and member of the board of directors of a number of firms, including lung cancer screening startup Oncimmune. Dr. Thestrup-Nielsen has worked with medical enterprises in both North America and Europe on IPOs, trade sales, acquisitions, and a range of investment transactions. He earned his M.D. from the University of Copenhagen School of Medicine, worked as a general and vascular surgeon for five years, and earned an MBA from the IMD in Lausanne, Switzerland.

Dr. Thestrup-Nielsen will play an active part in the creation of the Company's product strategy for Europe, the United States, and the rest of the world, including clinical development, market segmentation, go-to-market strategy, and regulatory strategy, in his advisory capacity with Mainz Biomed. He'll also advise on the creation of the worldwide commercial strategy and the clinical plan for future versions of Mainz Biomeds' ColoAlert test, as well as lead the clinical advisor's board once it's established.